Relaxin receptor structural determination to aid therapeutic development [ 1/1/2021 - 12/31/2024 ]

Research Grant

Brief description The receptor for the peptide hormone relaxin, RXFP1, is being targeted by numerous drug companies for the treatment of cardiovascular disease. However, the lack of molecular detail of how relaxin binds and activates RXFP1 is hindering new drug development. We will determine the structure of the complex of relaxin bound to RXFP1 and the mechanism by which this activates cells. The knowledge gained will aid in the design of new drugs targeting RXFP1 for the treatment of cardiovascular disease.

Funding Amount $1,249,114

Funding Scheme Ideas Grants

Chief Investigator Prof Ross Bathgate

Notes Ideas Grants